Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27082306 | 0.78 | MGLL (0.39) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL27166388 | 0.75 | KCNH2 (0.45) | KMT2A | |
| SCHEMBL30872608 | 0.71 | NOTUM (0.53) | KMT2AMEN1CCNB2CDK1CCNB1 | |
| SCHEMBL24013579 | 0.71 | ADRA1A (0.35) | KMT2AMEN1 | |
| SCHEMBL24409353 | 0.71 | CYP11B1 (0.33) | KMT2AMEN1 | |
| SCHEMBL9451016 | 0.71 | MEN1 (0.44) | KMT2AMEN1CCNB2CDK1CCNB1 | |
| SCHEMBL29503091 | 0.70 | CYP2C9 (0.47) | KMT2A | |
| SCHEMBL1964902 | 0.69 | MEN1 (0.50) | KMT2AMEN1CCNB2CDK1CCNB1 | |
| SCHEMBL24409428 | 0.69 | RAB9A (0.33) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL24409109 | 0.67 | ALDH1A1 (0.51) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327078-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117263945-A | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-113316578-B | Heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
| CN-113316578-A | Heterocyclic compounds, pharmaceutical compositions containing them, processes for their preparation and their use | 四川科伦博泰生物医药股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | KMT2A 3761/4885MEN1 25/4885CCNB2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.